Quantitative diffusion weighted MRI: A functional biomarker of nodal disease in Hodgkin lymphoma?

Cancer Biomarkers

Volumn 7, Issue 4-5, 2010, Pages 249-259

  Punwani, Shonit ^a,b   Prakash, Vineet ^a   Bainbridge, Alan ^a,b   Taylor, Stuart A ^a,b   Bandula, Steven ^a   Olsen, Oystein E ^c   Hain, Sharon F ^a   Shankar, Ananth ^a   Daw, Stephen ^a   Humphries, Paul ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

adolescent; child; Diffusion magnetic resonance imaging; lymphoma; positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CANCER STAGING; CHILD; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG UPTAKE; FEMALE; HODGKIN DISEASE; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHOOL CHILD;

ADOLESCENT; CHILD; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; HODGKIN DISEASE; HUMANS; LYMPH NODES; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TUMOR MARKERS, BIOLOGICAL;

EID: 79955613275     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2010-0197     Document Type: Article

References (31)

1. American Cancer Society. What are the key statistics about Hodgkin disease? Cancer Reference Information. 2009 [cited 2010 30th March 2010]; Available from: http://www.cancer. org/docroot/CRI/content/CRI-2-41x-What-Are- the-Key- Statistics-About-Hodgkin-Disease.asp?sitearea=
2. One-and five-year survival of patients diagnosed in 1991-95 and 1996-+99: less common cancers, sex and age, Eng-land and Wales. 2005 [cited 2010 30th March 2010]; Avail-able from: http://info.cancerresearchuk.org/cancerstats/ types/hodgkinslymphoma/survival/.
3. K. Bhatia, A. Sahdev and R.H. Reznek, Lymphoma of the spleen, Semin Ultrasound CTMR 28 (2007), 12-20. (Pubitemid 46176541)
4. A.K. Ng and P.M. Mauch, Late effects of Hodgkin's disease and its treatment, Cancer J 15 (2009), 164-168.
5. C Furth, I.G. Steffen, H. Amthauer, J. Ruf, D. Misch, S. Schönberger et al., Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial, J Clin Oncol 27 (2009), 4385-4391.
6. S.J. Vinnicombe and R.H. Reznek, Computerised tomogra-phy in the staging of Hodgkin's disease and non-Hodgkin's lymphoma, Eur J Nucl Med Mol Imaging 30(Suppl 1) (2003), S42-S55. (Pubitemid 36735762)
7. C la Fougère, W. Hundt, N. Bröckel, T. Pfluger, A. Haug, B. Scher et al., Value of PET/CT versus PET and CT performed as separate investigations in patients with Hodgkin's disease and non-Hodgkin's lymphoma, Eur J Nucl Med Mol Imaging 33 (2006), 1417-1425. (Pubitemid 44885407)
8. A. Kumral, N. Olgun, K.M. Uysal, F. Corapciofülu, H. Oren and F. Sarialiofülu, Assessment ofperipheral lymphad-enopathies: experience at a pediatric hematology-oncology department in Turkey, Pediatr Hematol Oncol 19 (2002), 21 1-218.
9. C.R. Isasi, P. Lu and M.D. Blaufox, A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma, Cancer 104 (2005), 1066-1074. (Pubitemid 41170236)
10. E. Kabickova, D. Sumerauer, E. Cumlivska, E. Drahokoupilo-va, M. Nekolna, M. Chanova et al., Comparison of 18F-FDG-PET and standard procedures for the pretreatment staging of children and adolescents with Hodgkin's disease, Eur J Nucl MedMol Imaging 33 (2006), 1025-1031. (Pubitemid 44215668)
11. J.S. Newman, I.R. Francis, M.S. Kaminski and R.L. Wahl, Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT, Radiology 190(1994), 111-116.
12. R. Thill, J. Neuerburg, U. Fabry, U. Cremerius, G. Wa-genknecht, D. Hellwig et al., [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma], Nuklearmedizin 36 (1997), 234-239. (Pubitemid 27489459)
13. D.A. Pierce and D.L. Preston, Radiation-related cancer risks at low doses among atomic bomb survivors, Radiat Res 154 (2000), 178-186. (Pubitemid 30612918)
14. D. Brenner, C Elliston, E. Hall and W. Berdon, Estimated risks of radiation-induced fatal cancer from pediatric CT,AJR Am J Roentgenol 176 (2001), 289-296. (Pubitemid 32105628)
15. R.A. Kleinerman, Cancerrisks following diagnostic andthera-peutic radiation exposure in children, Pediatr Radiol 36(Suppl 2) (2006), 121-125.
16. S. Punwani, S.A. Taylor, A. Bainbridge, V Prakash, S. Ban-dula, E. De Vita et al., Pediatric and Adolescent Lymphoma: Comparison of Whole-Body STIR Half-Fourier RARE MR Imaging with an Enhanced PET/CT Reference for Initial Stag-ing1, Radiology 255 (2010), 182-190.
17. P.D. Humphries, N.J. Sebire, M.J. Siegel and Ò.E. Olsen, Tu-mors in pediatric patients at diffusion-weighted MR imaging: apparent diffusion coefficient and tumor cellularity, Radiology 245 (2007), 848-854. (Pubitemid 350127356)
18. S. Li, H.-D. Xue, J. Li, F. Sun, B. Jiang, D. Liu et al., Ap-plication of whole body diffusion weighted MR imaging for diagnosis and staging of malignant lymphoma, Chin Med Sci J23 (2008), 138-144.
19. R. Bos, J.J.M. van Der Hoeven, E. van Der Wall, P. van Der Groep, PJ. van Diest, E.F.I. Comans et al., Biologic corre-lates of (18)fluorodeoxyglucose uptake in human breast can-cer measured by positron emission tomography, J Clin Oncol 20 (2002), 379-387. (Pubitemid 34072519)
20. T. Higashi, N. Tamaki, T. Torizuka, Y Nakamoto, H. Sakahara, T. Kimura et al., FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors, J Nucl Med 39 (1998), 1727-1735. (Pubitemid 28473521)
21. K. Ito, T. Kato, T. Ohta, M. Tadokoro, T. Yamada, M. Ikeda et al., Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity, Eur JNucl Med 23 (1996), 1372-1377. (Pubitemid 26340591)
22. R. Elstrom, L. Guan, G. Baker, K. Nakhoda, J.-A. Vergilio, H. Zhuang et al., Utility of FDG-PET scanning in lymphoma by WHO classification, Blood 101 (2003), 3875-3876. (Pubitemid 36857861)
23. M. Kleis, H. Daldrup-Link, K. Matthay, R. Goldsby, Y. Lu, T. Schuster et al., Diagnostic value of PET/CTforthe staging and restaging of pediatric tumors, Eur J Nucl Med Mol Imaging 36 (2009), 23-36.
24. M.E. Juweid, S. Stroobants, O.S. Hoekstra, F.M. Mottaghy, M. Dietlein, A. Guermazi et al., Use of positron emission tomographyforresponseassessmentoflymphoma: consensus of the Imaging Subcommittee ofInternational Harmonization Project in Lymphoma, J Clin Oncol 25 (2007), 571-578. (Pubitemid 350002965)
25. T Mori, H. Nomori, K. Ikeda, K. Kawanaka, S. Shiraishi, K. Katahira et al., Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography, J Thorac On-col 3 (2008), 358-364. (Pubitemid 351489475)
26. K.-C. Ho, G. Lin, J.-J. Wang, C.-H. Lai, C.-J. Chang and T-C. Yen, Correlation of apparent diffusion coefficients measured by 3T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer, Eur J Nucl Med Mol Imaging 36 (2009), 200-208.
27. TC. Kwee, T Takahara, P.R. Luijten and R.A.J. Nievelstein, ADC measurements of lymphnodes: Inter-and intra-observer reproducibility study and an overview of the literature, Eur J Radiol 75 (2010), 215-220.
28. N.C. Krak, R. Boellaard, O.S. Hoekstra, J.W. Twisk, C.J. Hoekstra and A.A. Lammertsma, Effects of ROI definition and reconstruction method on quantitative outcome and appli-cability in a response monitoring trial, Eur J Nucl Med Mol Imaging 32 (2005), 294-301. (Pubitemid 40562120)
29. W.A. Weber, S.I. Ziegler, R. Thodtmann, A.R. Hanauske and M. Schwaiger, Reproducibility of metabolic measurements in malignant tumors using FDG PET, J Nucl Med 40 (1999), 1771-1777. (Pubitemid 29523568)
30. E.M. Marom, R.F. Munden and M.T Truong, Interobserv-er and intraobserver variability of standardized uptake val-ue measurements in non-small-cell carcinoma lung cancer, J Thorac Imaging 21 (2006), 205-212. (Pubitemid 44258947)
31. C Nahmias and L.M. Wahl, Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors, J Nucl Med 49 (2008) 1804-1808.